NCT00654875

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

A 10 Week, Randomized, Double-blind, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg qd) to Twice Daily Dosing of Aliskiren (150 mg Bid) in Patients With Essential Hypertension.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 328 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will compare the safety and efficacy of once daily dosing of aliskiren to twice daily dosing of aliskiren in patients with moderate hypertension

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	Aliskiren	Aliskiren supplied in 150 mg and 300 mg tablets.
DRUG	Placebo to Aliskiren	Placebo to Aliskiren matching 150 and 300 mg tablets

Timeline

• Start date: 2008-03-01
• Primary completion: 2008-11-01
• Completion: 2008-11-01
• First posted: 2008-04-09
• Last updated: 2011-06-28
• Results posted: 2011-06-15

Locations

3 sites across 3 countries: United States, Germany, Spain